ImmunityBio (NASDAQ:IBRX - Get Free Report) had its price objective hoisted by equities researchers at Piper Sandler from $4.00 to $5.00 in a research note issued to investors on Monday, Benzinga reports. The firm currently has a "neutral" rating on the stock. Piper Sandler's price target would suggest a potential downside of 8.09% from the company's previous close.
ImmunityBio Stock Performance
NASDAQ IBRX traded down $0.63 on Monday, hitting $5.44. 4,426,664 shares of the stock traded hands, compared to its average volume of 4,024,637. The business's fifty day moving average is $4.50 and its two-hundred day moving average is $3.57. ImmunityBio has a 12 month low of $1.25 and a 12 month high of $6.93. The firm has a market capitalization of $3.67 billion, a price-to-earnings ratio of -4.69 and a beta of 1.24.
Hedge Funds Weigh In On ImmunityBio
Institutional investors and hedge funds have recently bought and sold shares of the company. Legal & General Group Plc boosted its holdings in shares of ImmunityBio by 2.2% in the fourth quarter. Legal & General Group Plc now owns 120,529 shares of the company's stock worth $605,000 after acquiring an additional 2,566 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of ImmunityBio by 43.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,393 shares of the company's stock worth $47,000 after acquiring an additional 2,844 shares during the period. UBS Group AG boosted its holdings in shares of ImmunityBio by 7.4% in the fourth quarter. UBS Group AG now owns 42,712 shares of the company's stock worth $214,000 after acquiring an additional 2,930 shares during the period. Amalgamated Bank boosted its holdings in shares of ImmunityBio by 21.9% in the fourth quarter. Amalgamated Bank now owns 17,752 shares of the company's stock worth $89,000 after acquiring an additional 3,186 shares during the period. Finally, Barclays PLC raised its position in shares of ImmunityBio by 1.3% in the fourth quarter. Barclays PLC now owns 256,365 shares of the company's stock worth $1,300,000 after buying an additional 3,335 shares in the last quarter. 8.58% of the stock is owned by institutional investors.
About ImmunityBio
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases in the United States and Europe. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine technologies, toll-Like receptor activating adjuvants, natural killer cells, and damage-associated molecular patterns inducers.
Featured Articles
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
